Quantifying Downstream Capacity Crunch: Column Resins Are Implicated by Many Experts As the Source of Biomanufacturing's Woes

摘要

In today's biomanufacturing environment, down-stream capacity has become a partial roadblock to nearly all CMOs (94%) and more than half (61%) of biotherapeutic developers (Figure 1). Extensive data from 434 biopharmaceutical manufacturers in 32 countries is summarized in BioPlan Associates' just-released 5th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production. The report shows, among other trends, that biomanufacturing facilities are experiencing a dramatic increasein downstream bottlenecks.